163 related articles for article (PubMed ID: 16439987)
1. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Hsieh DS; Loh SH; Chen A; Yao CW; Yen CY
Mod Pathol; 2006 Mar; 19(3):447-52. PubMed ID: 16439987
[TBL] [Abstract][Full Text] [Related]
2. Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Yao CW; Loh SH; Cheng MF; Hsieh DS; Bai CY
Int J Gynecol Pathol; 2006 Apr; 25(2):140-6. PubMed ID: 16633062
[TBL] [Abstract][Full Text] [Related]
3. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
4. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
[TBL] [Abstract][Full Text] [Related]
5. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
6. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
7. Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors.
Shigemasa K; Tanimoto H; Underwood LJ; Parmley TH; Arihiro K; Ohama K; O'Brien TJ
Int J Gynecol Cancer; 2001; 11(6):454-61. PubMed ID: 11906548
[TBL] [Abstract][Full Text] [Related]
8. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
[TBL] [Abstract][Full Text] [Related]
9. TTF-1 expression in primary ovarian epithelial neoplasia.
Graham AD; Williams AR; Salter DM
Histopathology; 2006 May; 48(6):764-5. PubMed ID: 16681695
[No Abstract] [Full Text] [Related]
10. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
Lin CK; Chao TK; Lai HC; Lee HS
Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057
[TBL] [Abstract][Full Text] [Related]
11. [Pathology of ovarian cancer].
Kaku T; Ogawa S; Hirakawa T; Ohishi Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():471-5. PubMed ID: 15535290
[No Abstract] [Full Text] [Related]
12. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
13. [Pathology of ovarian cancer].
Kaku T; Watanabe S; Ohishi Y
Nihon Rinsho; 2012 Jun; 70 Suppl 4():512-6. PubMed ID: 23156300
[No Abstract] [Full Text] [Related]
14. Increased expression of protease M in ovarian tumors.
Tanimoto H; Underwood LJ; Shigemasa K; Parmley TH; O'Brien TJ
Tumour Biol; 2001; 22(1):11-8. PubMed ID: 11054022
[TBL] [Abstract][Full Text] [Related]
15. Ovarian yolk sac tumors in older women arising from epithelial ovarian tumors or with no detectable epithelial component.
Roth LM; Talerman A; Levy T; Sukmanov O; Czernobilsky B
Int J Gynecol Pathol; 2011 Sep; 30(5):442-51. PubMed ID: 21804392
[TBL] [Abstract][Full Text] [Related]
16. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer.
Amsterdam A; Shezen E; Raanan C; Schreiber L; Prus D; Slilat Y; Ben-Arie A; Seger R
Int J Oncol; 2011 Sep; 39(3):649-56. PubMed ID: 21687944
[TBL] [Abstract][Full Text] [Related]
17. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters.
Lin CK; Su HY; Tsai WC; Sheu LF; Jin JS
Dis Markers; 2008; 25(1):17-26. PubMed ID: 18776588
[TBL] [Abstract][Full Text] [Related]
18. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins.
Riedel I; Czernobilsky B; Lifschitz-Mercer B; Roth LM; Wu XR; Sun TT; Moll R
Virchows Arch; 2001 Feb; 438(2):181-91. PubMed ID: 11253121
[TBL] [Abstract][Full Text] [Related]
19. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer.
Ginath S; Menczer J; Friedmann Y; Aingorn H; Aviv A; Tajima K; Dantes A; Glezerman M; Vlodavsky I; Amsterdam A
Int J Oncol; 2001 Jun; 18(6):1133-44. PubMed ID: 11351242
[TBL] [Abstract][Full Text] [Related]
20. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]